Is CERS a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

570 people get CERS articles and Market Currents by email alert.

Get email alerts on CERS »

HEADLINES:

Cerus Management Discusses Q1 2013 Results - Earnings Call Transcript
Wed, May 1
Cerus Corporation Reports First Quarter 2013 Results

Business Wire (Apr 30, 2013)
Cerus Announces FDA Agreement on Modular Premarket Approval (PMA) Application Submission Process for INTERCEPT Platelets

Business Wire (Apr 24, 2013)
Cerus to Release First Quarter 2013 Results on April 30, 2013

Business Wire (Apr 17, 2013)
Traders Are Cautious Of These Illiquid Stocks With Troubling Inventory Trends
Kapitall • Tue, Apr 9 • 3 Comments
Swissmedic and Swiss Red Cross Present National Haemovigilance Data Showing Favourable Safety Profile for INTERCEPT-Treated Platelet Components

Business Wire (Apr 3, 2013)
Cerus Signs INTERCEPT Platelet Agreements With Two Key Blood Component Suppliers in Germany and Austria

Business Wire (Mar 15, 2013)
Cerus Prices Public Offering of Common Stock

Business Wire (Mar 14, 2013)
Cerus Announces Proposed Public Offering of Common Stock

Business Wire (Mar 13, 2013)
4 Biotech Stocks Looking To Heat Up In Time For Summer
Craig Keolanui • Sun, Mar 10 • 4 Comments
Cerus Management Discusses Q4 2012 Results - Earnings Call Transcript
Thu, Feb 28
Cerus Corporation Reports Fourth Quarter and Year-End 2012 Results

Business Wire (Feb 28, 2013)
Cerus to Present at the Cowen and Company 33rd Annual Health Care Conference on March 6, 2013

Business Wire (Feb 27, 2013)
Cerus to Release Fourth Quarter and Year-End 2012 Results on February 28, 2013

Business Wire (Feb 14, 2013)
2 Speculative Biotech Stocks To Consider In The Wake Of Early-Stage Developments
Matt Schilling • Thu, Dec 13, 2012 • 8 Comments
Cerus Announces FDA Agreement on Modular Premarket Approval Application (PMA) Submission Process for INTERCEPT Plasma

Business Wire (Dec 13, 2012)
Cerus Signs Agreement With Swiss Red Cross for Initial Deployment of the INTERCEPT Blood System for Plasma

Business Wire (Dec 4, 2012)
Cerus to Present at the Piper Jaffray Healthcare Conference on November 28, 2012

Business Wire (Nov 21, 2012)
Cerus to Present at the Stephens Fall Investment Conference on November 14, 2012

Business Wire (Nov 8, 2012)
Cerus to Present at the Lazard Capital Markets 9th Annual Healthcare Conference on November 14, 2012

Business Wire (Nov 8, 2012)

To learn more about Seeking Alpha Pro, click here.

Another Solid Speculative $3.50 Play In The Biotech Sector
Bret Jensen • Sat, Jul 14, 2012 • 15 Comments
My Favorite Stock Idea For The Next Decade
Steven Bulwa • Wed, Apr 4, 2012 • 16 Comments
Why Cerus Is My Stock of the Year
Michael Shulman • Wed, Jan 5, 2011 • 15 Comments
Cerus: An Unknown Gem That's Primed for a Boost
Michael Shulman • Tue, May 18, 2010 • 3 Comments
Adoption of Cerus' Technology Makes Its Valuation Look Ridiculous
Michael Shulman • Tue, Feb 9, 2010 • 6 Comments

Traders Are Cautious Of These Illiquid Stocks With Troubling Inventory Trends
Kapitall • Tue, Apr 9 • 3 Comments
4 Biotech Stocks Looking To Heat Up In Time For Summer
Craig Keolanui • Sun, Mar 10 • 4 Comments
2 Speculative Biotech Stocks To Consider In The Wake Of Early-Stage Developments
Matt Schilling • Thu, Dec 13, 2012 • 8 Comments
5 High-Growth Biotechnology Stocks That Analysts Strongly Favor
ZetaKap • Sat, Aug 25, 2012 • 21 Comments
6 Rallying Biotech Stocks With Strong Receivable Trends
Kapitall • Sun, Jul 22, 2012 • 1 Comment
7 Growing Biotech Small Caps With Strong Analyst Confidence
ZetaKap • Mon, Jun 11, 2012 • 2 Comments
21 Outperforming Hedge Fund Stock Picks Reporting Earnings Next Week
Kapitall • Thu, Apr 26, 2012
Where The Market Is Headed From Here
Steven Bulwa • Tue, Apr 17, 2012 • 9 Comments
5 Stocks Under $12 That Created New 52-Week Highs On Double Volume On Friday
Kinetic Investments • Mon, Mar 19, 2012 • 4 Comments
12 Highly Shorted Biotech Stocks Being Snapped Up By Insiders
Kapitall • Wed, Feb 15, 2012 • 1 Comment
10 Biotech Stocks With Bearish Short Trends
Kapitall • Mon, Dec 19, 2011 • 1 Comment
9 Stocks Under $3 With Bullish Options Sentiment and Short Trends
Kapitall • Mon, Aug 8, 2011 • 3 Comments
Low-Priced Biotech Stocks With Insider Buying
Rougemont • Fri, Mar 18, 2011 • 3 Comments
Which of These Small Stocks Can Climb Even Higher?
StreetAuthority • Fri, Jan 28, 2011 • 4 Comments
9 Biotech Stocks for 2011
Michael Shulman • Thu, Jan 13, 2011 • 31 Comments
FOMC Minutes and How to Play the Non-Rebound Rebound
Michael Shulman • Wed, Nov 24, 2010 • 5 Comments
Jobless Claims Cut Through the Noise
Michael Shulman • Thu, Nov 4, 2010 • 2 Comments
15 Biotech Stocks With the Lowest Put/Call Ratios
Kapitall • Wed, Oct 13, 2010 • 3 Comments
Tengion's IPO Comes In Well Below Initial Range: Biotech's Latest Deals, Financings
The Burrill Report • Sun, Apr 11, 2010
The Return of Buy and Hold?
Michael Shulman • Tue, Apr 6, 2010 • 12 Comments

Cerus Management Discusses Q1 2013 Results - Earnings Call Transcript
Wed, May 1
Cerus Management Discusses Q4 2012 Results - Earnings Call Transcript
Thu, Feb 28
Cerus Management Discusses Q3 2012 Results - Earnings Call Transcript
Wed, Nov 7, 2012
Cerus Management Discusses Q2 2012 Results - Earnings Call Transcript
Thu, Aug 2, 2012

Cerus Corporation Reports First Quarter 2013 Results

Business Wire (Apr 30, 2013)
Cerus Announces FDA Agreement on Modular Premarket Approval (PMA) Application Submission Process for INTERCEPT Platelets

Business Wire (Apr 24, 2013)
Cerus to Release First Quarter 2013 Results on April 30, 2013

Business Wire (Apr 17, 2013)
Swissmedic and Swiss Red Cross Present National Haemovigilance Data Showing Favourable Safety Profile for INTERCEPT-Treated Platelet Components

Business Wire (Apr 3, 2013)
Cerus Signs INTERCEPT Platelet Agreements With Two Key Blood Component Suppliers in Germany and Austria

Business Wire (Mar 15, 2013)
Cerus Prices Public Offering of Common Stock

Business Wire (Mar 14, 2013)
Cerus Announces Proposed Public Offering of Common Stock

Business Wire (Mar 13, 2013)
Cerus Corporation Reports Fourth Quarter and Year-End 2012 Results

Business Wire (Feb 28, 2013)
Cerus to Present at the Cowen and Company 33rd Annual Health Care Conference on March 6, 2013

Business Wire (Feb 27, 2013)
Cerus to Release Fourth Quarter and Year-End 2012 Results on February 28, 2013

Business Wire (Feb 14, 2013)
Cerus Announces FDA Agreement on Modular Premarket Approval Application (PMA) Submission Process for INTERCEPT Plasma

Business Wire (Dec 13, 2012)
Cerus Signs Agreement With Swiss Red Cross for Initial Deployment of the INTERCEPT Blood System for Plasma

Business Wire (Dec 4, 2012)
Cerus to Present at the Piper Jaffray Healthcare Conference on November 28, 2012

Business Wire (Nov 21, 2012)
Cerus to Present at the Stephens Fall Investment Conference on November 14, 2012

Business Wire (Nov 8, 2012)
Cerus to Present at the Lazard Capital Markets 9th Annual Healthcare Conference on November 14, 2012

Business Wire (Nov 8, 2012)
Cerus Corporation Reports Third Quarter 2012 Results

Business Wire (Nov 7, 2012)
Cerus to Postpone Third Quarter 2012 Conference Call and Earnings Release Due to Expectation of Severe Weather

Business Wire (Oct 29, 2012)
Cerus Appoints Chrystal Menard as Chief Legal Officer

Business Wire (Oct 25, 2012)
Cerus to Release Third Quarter Results on October 30, 2012

Business Wire (Oct 16, 2012)
Cerus to Partner with American Red Cross and Blood Systems Incorporated to Commercialize INTERCEPT Plasma for Thrombotic Thrombocytopenic Purpura (TTP) Orphan Indication

Business Wire (Sep 11, 2012)

CERS vs. ETF Alternatives

Company Description

Currently, there's no company description for CERS.

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, May 1, 6:18 PM More on Cerus (CERS): Q1 misses across the board, despite a 12% Y/Y increase total sales. Gross margins jumped to 48% from 37%, driven primarily by lower product costs on improved overhead and higher manufacturing levels during H212. This wasn't enough to offset an increase in operating expenses however, due largely to regulatory activities for the submission of its INTERCEPT platelet and plasma modular PMA applications in the U.S. Operating losses were $5M, compared to $4.6M the previous year. Read more on earnings here: Earnings Call Transcript. Comment! [Healthcare, Earnings]
Wednesday, May 1, 4:42 AM Cerus (CERS): Q1 EPS of -$0.17 misses by $0.09. Revenue of $9.7M misses by $0.4M. (PR) 1 Comment [Earnings, Breaking News, Healthcare]
Wednesday, April 24, 10:49 AM The FDA accepts Cerus' (CERS +5.9%) outline of its Premarket Approval application for the INTERCEPT Blood System for platelets which is already in use by customers in 16 countries. Comment! [On the Move, Healthcare]
Thursday, March 14, 11:42 AM Cerus (CERS +2.9%) pushes nearer to its 52-week high after the company prices its secondary offering of around 8.3M shares at $4.20 each, a 5% discount to yesterday's close. The proceeds from the $35M offering, announced yesterday, will be used to fund the research and marketing of its Intercept Blood System, as well as for various other corporate purposes. Comment! [Healthcare, On the Move]
Wednesday, March 13, 4:54 PM Cerus (CERS) announces a secondary offering for an undisclosed amount. The company anticipates using the net proceeds for clinical development and other R&D and marketing activities related to its Intercept Blood System, plus other general corporate purposes. CERS may also use a portion of the net proceeds from the offering to prepay the remaining outstanding indebtedness under its growth capital loan with Comerica Bank. Cowen is acting as sole book-runner. Shares -0.5% AH. Comment! [Healthcare]
Friday, March 1, 4:07 PM Cerus (CERS +11%) closes out near its higs for the day after beating on its Q4 result late yesterday. Net sales grew by 6% Y/Y, driven by 14% growth in demand for Incercept disposable kits. Gross margins on product sales were 51%, compared to 37% for Q411. 1 Comment [Healthcare, Earnings, On the Move]
Friday, March 1, 9:10 AM Premarket gainers: ISRG +9%. SHS +8%. CERS +8%. DECK +8%. SQNM +7%. BBY +6%. PGH +5%.
Losers: AT -34%. FWLT -17%. OVTI -15%. RNIN -14%. IEP -12%. ENMD -12%. YOKU -11%. SD -8%. LYG -8%. CWH -6%. RBS -6%. DB -5%. Comment! [On the Move]
Thursday, February 28, 5:41 PM Cerus (CERS): Q4 EPS of -$0.07 beats by $0.01. Revenue of $10.5M (+6% Y/Y) beats by $0.7M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Thursday, December 13, 2012, 1:05 PM Cerus (CERS +2.8%) says the FDA has accepted its proposed modular Premarket Approval application shell - an outline of the application process defining the structure, content and timing of each module - for review of its Intercept Blood System for plasma. The agency's approval of a shell was required prior to initiation of a modular PMA submission, thus enabling CERS to proceed with an application that addresses multiple indications of plasma use for the system. Comment! [Healthcare, On the Move]
Wednesday, February 29, 2012, 9:14 AM Premarket gainers: CERS +10%. NKTR +10%. VVUS +6%. CHTP +5%. MDW +5%. IRE +3%. NBG +3%.
Losers: CEDC -28%. SODA -12%. GNTX -10%. CPST -8%. FSLR -7%. KOG -6%. TAL -5%. EXLP -5%. PANL -5%. KYN -5%. MHR -4%. 1 Comment [On the Move]
Wednesday, February 29, 2012, 9:02 AM Cerus (CERS) +8.2% premarket after reporting a Q4 EPS loss of $0.16 vs. consensus estimate loss of $0.09, and revenue of $10.4M vs. consensus $8.2M. Baird upgrades shares to Outperform from Neutral and raises its target price to $6 from $3, saying that while 2012 guidance is conservative, market dynamics are such that guidance should be a "lay-up." Comment! [Healthcare, Earnings, On the Move]
Monday, October 3, 2011, 3:30 PM It's been a wild ride today for pharmaceutical developer Vermillion (VRML), jumping +19% at the open on positive preliminary results for its PAD drug Vasclir, only to reverse course and tumble -13% as the biotech sector continues to collapse. Other biotech shares getting hit today: Cerus (CERS -5.2%), EXACT Sciences (EXAS -5.2%), Quest Diagnostics (DGX -5.2%), Gen-Probe (GPRO -3.8%), and (CPHD -2.6%). Comment! [Healthcare, On the Move]
Friday, March 4, 2011, 9:00 AM Premarket gainers: SPRD +11%. RAME +9%. ALTH +8%. HERO +5%. CGV +4%. NGD +3%.
Losers: CERS -12%. CTIC -11%. BPAX -10%. MRVL -7%. CEDC -6%. EVEP -4%. DPM -4%. KT -3%. FN -3%. KOG -3%. VE -3%. DX -3%. Comment!
Thursday, September 2, 2010, 9:00 AM Premarket gainers: OREX +27%. BKC +21%. CRME +12%. RNN +12%. CERS +8%. CTIC +5%. WEN +4%. MPEL +4%.
Losers: PSS -6%. Comment!
Tuesday, March 9, 2010, 9:00 AM Premarket gainers: FEED +19%. CERS +12%. CPE +9%. CELM +6%. GGP +5%.
Losers: MVIS -10%. TSEM -7%. AGT -6%. PCX -6%. IRE -6%. PLD -5%. AIB -5%. EJ -4%. CTIC -4%. Comment!
Wednesday, August 19, 2009, 11:04 AM Cerus (CERS +70%) soars after Swiss regulators approve its Intercept blood system, which lengthens platelets' shelf life by two days to a week by inactivating blood-borne pathogens. Drug is not yet available in U.S. Comment!

Jim Van Meerten
$CERS - 96% Barchart technical buy signal - 15 new highs and up 40.95% in the last month - Relative Strength Index 85.02%
Mar 15, 12:44 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
5 High-Growth Biotechnology Stocks That Analysts Strongly Favor http://bit.ly/QcrgYX $CERS $CTIC $MACK $PTIE $ZLCS @ZetaKap
8/25/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
7 Growing Biotech Small Caps With Strong Analyst Confidence http://bit.ly/OlxAd8 $ANIK $CRTX $CTIC $BSTC $CERS $EBS $CORT @ZetaKap
6/11/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Steven Bulwa
CERS in the news http://yhoo.it/JXwO7A
4/30/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Steven Bulwa
CERS News. http://yhoo.it/IB3nDO
4/24/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Steven Bulwa
Cantor Fitzgerald Starts Cerus (CERS) at Buy; Potential Game-Changer in Blood
4/17/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Joshua Hayes
Big Wave Trading Portfolio Update and Top Current Holdings http://bit.ly/HxVLSk SWHC KORS BVSN RF AVD LNKD EPAM SUNH CERS CIS LHCG CCU
3/31/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Joshua Hayes
Big Wave Trading Portfolio Update and Top Current Holdings http://bit.ly/GVErtI KORS SWHC RF AVD LNKD CERS LHCG ULTA CPWM CRMT
3/24/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Joshua Hayes
Big Wave Trading Portfolio Update and Top Current Holdings http://bit.ly/ycALVz KORS SWHC RF LHCG AVD SUNH CERS CRMT
3/18/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Joshua Hayes
$CMC $RPTP $MGN $OWW $PKT $LTS $ANLY $CERS $HW $NTE $CFX $GHDX $ALLT $ONE $CFX $MELI $PRIM $TASR some beautiful chart patterns out there.
12/6/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

CERS Cerus Corporation

CERS

Cerus Corporation